Full Text View
Tabular View
No Study Results Posted
Related Studies
Longitudinal Study of Vaginal Flora
This study has been completed.
Study NCT00340275   Information provided by National Institutes of Health Clinical Center (CC)
First Received: June 19, 2006   Last Updated: August 24, 2009   History of Changes

June 19, 2006
August 24, 2009
April 1999
September 2007   (final data collection date for primary outcome measure)
 
Response rate at six months, defined as no longer satisfying blood count criteria for SAA.
Complete list of historical versions of study NCT00340275 on ClinicalTrials.gov Archive Site
 
Relapse, robustness of the hematopoietic recovery at three and six months, three months responses, survival, and clonal evolution to myelodysplasia and acute leukemia.
 
Longitudinal Study of Vaginal Flora
Longitudinal Study of Vaginal Flora

Bacterial vaginosis is a syndrome manifested by adverse alterations in vaginal microbial flora. It is present in 10 to 25% of women in the general population, and is the most common vaginal infection. It has been associated with a number of adverse sequelae in reproductive health including acquisition of HIV, pelvic inflammatory disease, cervical dysplasia, and complications of gynecological procedures. During pregnancy it has been associated with an increased risk of preterm birth an postpartum maternal infection. However, the vaginal microbial flora remains poorly understood. Information on variation in microbial flora and its association with BV from a longitudinal study is unavailable. This prospective observational study aims to advance our knowledge of the natural history and abnormal alteration in vaginal microbial flora, and to identify risk factors that are associated with these changes. A total of 5500 healthy, non-pregnant women of reproductive age will be enrolled and followed up in Birmingham, Alabama, for one year (baseline visit plus once every three months afterwards, totaling 5 visits). Detailed information on sociodemographic status, medical history, hygiene practice, sexual behavior and psychosocial stress will be collected through in-person interviews. Routine gynecological and dental examinations will be carried out during the study visits. Samples of vaginal secretion and blood will be collected. Laboratory tests to quantify vaginal microbial flora and to identify infection of bacterial vaginosis as well as common sexually transmitted diseases will be conducted. This project is expected to complete in 5 years.

Bacterial vaginosis is a syndrome manifested by adverse alterations in vaginal microbial flora. It is present in 10 to 25% of women in the general population, and is the most common vaginal infection. It has been associated with a number of adverse sequelae in reproductive health including acquisition of HIV, pelvic inflammatory disease, cervical dysplasia, and complications of gynecological procedures. During pregnancy it has been associated with an increased risk of preterm birth and postpartum maternal infection. However, the vaginal microbial flora remains poorly understood. Information on variation in microbial flora and its association with BV from a longitudinal study is unavailable. This prospective observational study aims to advance our knowledge of the natural history and abnormal alteration in vaginal microbial flora, and to identify risk factors that are associated with these changes. A total of 5500 healthy, non-pregnant women of reproductive age will be enrolled and followed up in Birmingham, Alabama, for one year (baseline visit plus once every three months afterwards, totaling 5 visits). Detailed information on sociodemographic status, medical history, hygiene practice, sexual behavior and psychosocial stress will be collected through in-person interviews. Routine gynecological and dental examinations will be carried out during the study visits. Samples of vaginal secretion and blood will be collected. Laboratory tests to quantify vaginal microbial flora and to identify infection of bacterial vaginosis as well as common sexually transmitted diseases will be conducted. This project is expected to complete in 5 years.

 
Observational
 
Vaginal Flora
 
 
 

*   Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
 
Completed
5500
 
September 2007   (final data collection date for primary outcome measure)
  • ELIGIBILITY CRITERIA:
  • Females, age 15-44.
  • Since bacterial vaginosis is primarily a condition of reproductive-age women, this study will be restricted to women regarded by demographers as reproductive age.
  • Non-pregnant women whose last menstrual period is later than expected will undergo a urine pregnancy test. Women who become pregnant while on study will complete their next regularly scheduled study visit, following which their participation will terminate.

EXCLUSION CRITERIA:

  1. Immunocompromised status

    Receiving or expected to receive in the next 12 months cytotoxic or immunosuppressive drugs.

    Receiving or expected to receive in the next 12 months one or more 30-day courses of corticosteroids.

    Congenital or acquired immune deficiency; known HIV positivity.

  2. Primary or secondary affective disorder, psychosis, emotional or intellectual limitations that preclude informed consent.
  3. Non-fluency in English.
  4. Post-menopausal (natural or surgical).
  5. Status post hysterectomy or expected to undergo hysterectomy in the next 12 months.
  6. Status post pelvic radiotherapy, or expected to undergo pelvic radiotherapy in the next 12 months.
  7. Receiving or expected to receive chronic (daily for at least 30 days) antibiotics in the next 12 months.
  8. Planning to move out of the area in the next 12 months.
  9. Participating or expected to participate during the next 12 months in a clinical trial in which antibiotics or topical microbicides will be administered in a blinded manner.
  10. Women who unexpectedly develop one of these conditions during their participation will continue to be followed, unless a specific contraindication arises.
Female
15 Years to 44 Years
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00340275
 
999999023, OH99-CH-N023
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
 
 
National Institutes of Health Clinical Center (CC)
June 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP